Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England

There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub‐lineage of the Omicron SARS‐CoV‐2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Harman, Katie, Nash, Sophie Grace, Webster, Harriet H., Groves, Natalie, Hardstaff, Jo, Bridgen, Jessica, Blomquist, Paula B., Hope, Russell, Ashano, Efejiro, Myers, Richard, Rokadiya, Sakib, Hopkins, Susan, Brown, Colin S., Chand, Meera, Dabrera, Gavin, Thelwall, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225304/
https://www.ncbi.nlm.nih.gov/pubmed/37246147
http://dx.doi.org/10.1111/irv.13150
Descripción
Sumario:There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub‐lineage of the Omicron SARS‐CoV‐2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub‐lineages.

Ejemplares similares